CellTrak Technologies, Inc., a leading provider of integrated mobile solutions for the home healthcare, hospice, and private duty market segments in healthcare, today announced that the United States Patent and Trademark Office has issued Patent Number 8,019,622 to CellTrak. Titled “Home Health Point of Care and Administration System,” the 8,019,622 patent is directed to aspects of CellTrak’s mobile staff scheduling, tracking and travel management, electronic visit record and care plan administration, and communications systems. Read more…
U.S. HealthWorks Medical Group, a leading operator of occupational health and urgent care centers in the nation, today announced that they are offering H1N1 vaccine shots for $15 per shot for both walk-ins — no appointments necessary — and onsite visits to businesses. Health centers in Spokane have new quantities of H1N1 vaccine available.
“With many experts expecting a new wave of H1N1 infections during the traditional flu season from now until March, we are doing our part by offering shots at $15 each during National Influenza Vaccination Week,” said Dr. Leonard Okun, National Medical Director for U.S. HealthWorks. “And because we’re not a public agency, U.S. HealthWorks isn’t overcrowded so you can avoid the long lines.”
King Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA is the first FDA-approved long-acting opioid that is designed to reduce drug liking and euphoria when tampered with by crushing or chewing.
Utilizing King’s proprietary technology, EMBEDA contains extended-release morphine pellets, each with an inner core of naltrexone hydrochloride, an opioid receptor antagonist. If taken as directed, the morphine relieves pain while the sequestered naltrexone hydrochloride passes through the body with no intended clinical effect. If EMBEDA is crushed or chewed, the naltrexone is released and absorbed with the morphine, reversing the morphine’s subjective and analgesic effects. The clinical significance of the degree of this reduction has not been established, and there is no evidence that the naltrexone in EMBEDA reduces the abuse liability of EMBEDA.
